Intelligence · Clinical Development
Pipeline search results
Programs matching “breast-cancer” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 272 pipeline programs matching "breast-cancer" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
HLX02
Shanghai Henlius Biotech
Breast Cancer
1 trial -
Ixabepilone + Capecitabine
Semnur Pharmaceuticals
Breast Cancer
1 trial -
JS001
Shanghai University of Traditional Chinese Medicine
Triple-Negative Breast Cancer
1 trial -
MO43110
Hoffmann-La Roche
Early Breast Cancer
1 trial -
Methylthioninium
Shandong Suncadia Medicine Co.,
Breast Cancer
1 trial -
Myocet
Teva Pharma GmbH
Early Primary Breast Cancer
1 trial -
NKTR-102
Nektar Therapeutics UK Limited
Locally Recurrent Breast Cancer
1 trial -
Olaparib
AstraZeneca
Breast Cancer Metastatic
1 trial -
PF-05280014
Pfizer
Metastatic Breast Cancer
1 trial -
Palazestrant
Olema Pharmaceuticals
Breast Cancer
3 trials -
Palbociclib
Pfizer
Metastatic Breast Cancer
1 trial -
Pembrolizumab (K)
Merck KGaA, Darmstadt, Germany
Breast Cancer
1 trial -
Placebo
Amgen
Breast Cancer
1 trial -
Raloxifene - Usual
Lxo Ireland Designated Activity Company
Breast Cancer
1 trial -
Ribociclib
Novartis Pharmaceuticals
Breast Cancer
1 trial -
Ribociclib
Novartis Pharmaceuticals
Advanced, Metastatic Breast Cancer
1 trial -
SV-BR-1-GM
BriaCell Therapeutics
Breast Cancer
2 trials -
Sacituzumab Govitecan-hziy
Gilead Sciences Ireland UC
Triple Negative Breast Cancer
1 trial -
TAP-144-SR(6M)
Takeda
Premenopausal Breast Cancer
1 trial -
Tamoxifen
International Peace Maternity and Child Health Hospital
Breast Cancer
1 trial -
Tamoxifen
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Breast Cancer Female
1 trial -
Taselisib
Hoffmann-La Roche
Breast Cancer
1 trial -
Taxotere , Epirubicin
Hospital Authority, Hong Kong
Breast Cancer
1 trial -
Trastuzumab
Hoffmann-La Roche
Metastatic Breast Cancer
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.